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Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a heterogeneous, 
progressive X-linked recessively inherited lysosomal storage disease that is caused by a deﬁ  -
ciency of the enzyme iduronate-2-sulfatase, resulting in abnormal tissue accumulation of the 
glycosaminoglycans, dermatan sulfate and heparan sulfate. The disorder results from muta-
tions in IDS, which is located at Xq28. Over 300 pathogenic mutations have been identiﬁ  ed to 
date. The management of MPS II requires multidisciplinary care because of the many affected 
organ systems. Replacement of functional enzyme to involved tissues has been a focus of vari-
ous therapies for several decades. The transplantation of hematopoietic stem cells provides 
enzymatic reconstitution in many target tissues, but the clinical response has been disappoint-
ing. Recently, enzyme replacement therapy with recombinant human iduronate-2-sulfatase 
(idursulfase, Elaprase®; Shire HGT Pharmaceuticals, Cambridge MA, USA), was approved by 
the in the US and Europe as a safe and effective treatment for individuals with MPS II. This 
review presents a comprehensive overview of MPS II and summarizes the recent literature on 
therapy for the disease.
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Introduction
The mucopolysaccharidoses are a group of lysosomal storage diseases characterized 
by a deﬁ  ciency of enzymes responsible for the stepwise degradation of glycosamino-
glycans. With the exception of mucopolysaccharidosis type II (MPS II; Hunter syn-
drome), an X-linked recessively inherited disorder, all are inherited in an autosomal 
recessive manner. MPS II is a heterogeneous, progressive lysosomal storage disease 
that results from deﬁ  ciency of the enzyme, iduronate-2-sulfatase, which cleaves an 
O-linked sulfate from dermatan sulfate and heparan sulfate (Neufeld and Muenzer 
2001). Consequently, dermatan sulfate and heparan sulfate progressively accumulate 
in the lysosomes, leading to the phenotypic features observed in the disease. The 
disease occurs with an incidence of approximately 1.3 cases per 100,000 male live 
births in Germany and the Netherlands (Poorthuis et al 1999; Baehner et al 2005). 
Approximately two-thirds of cases exhibit central nervous system (CNS) involvement, 
representing more severe phenotypes of the disease (Wraith et al 2007, 2008). A few 
affected females have also been reported, often in association with extremely skewed 
X-inactivation (Tuschl et al 2005). The disorder results from mutations in IDS, which 
is located at Xq28. Over 300 mutations have been identiﬁ  ed to date, many of which 
are private and associated with a signiﬁ  cant new mutation rate in the male genome 
(Froissart et al 2007).
Hematopoietic stem cell transplantation (HSCT) has been performed in numerous 
individuals with varying degrees of severity of MPS II, but limited success and signiﬁ  -
cant risk. Enzyme replacement therapy (ERT) involves the intravenous administration 
of a puriﬁ  ed, carbohydrate-modiﬁ  ed, recombinant human enzyme into individuals in Biologics: Targets & Therapy 2008:2(2) 312
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whom the enzyme is missing or defective. The recombinant 
enzyme undergoes receptor mediated cell uptake and sub-
sequent intracellular trafﬁ  cking into the lysosomes, where 
it carries out its speciﬁ  c function. ERT has been used suc-
cessfully for the primary treatment of Gaucher disease, Fabry 
disease, and mucopolysaccharidosis types I and VI. Recom-
binant iduronate-2-sulfatase (idursulfase, Elaprase®; Shire 
HGT Pharmaceuticals, Cambridge, MA, USA) was approved 
in July, 2006 in the US and January, 2007 in Europe as a safe 
and effective treatment for individuals with MPS II.
This review presents a comprehensive overview of MPS 
II and summarizes the recent literature on therapy, speciﬁ  -
cally ERT, for the disease.
Clinical features
Two clinical forms of MPS II have been historically rec-
ognized, attenuated and severe, which were primarily dis-
tinguished by the presence of CNS involvement. However, 
MPS II is more appropriately considered a heterogeneous 
disorder with a broad spectrum of clinical features. Even 
individuals with attenuated phenotypes of the disease may 
experience significant morbidity and limitation of life 
expectancy.
Individuals with attenuated phenotypes of MPS II do 
not exhibit CNS impairment. A signiﬁ  cant body of work 
prepared by Young and Harper in the 1980s reported a 
mean age of recognition of symptoms of 4.3 years, the most 
common presenting feature being coarse facial appearance 
(Young and Harper 1982; Young et al 1982). More recently, 
Schwartz and colleagues reported a median age of recognition 
of symptoms of 3.25 years in their patients with attenuated 
disease (Schwartz et al 2007). Despite reported mean ages 
of death from 17 to 21.7 years in this population, survival 
well into adulthood is not unexpected (Young and Harper 
1982; Young et al 1982; Schwartz et al 2007). Conversely, 
individuals with severe MPS II demonstrate clinically 
signiﬁ  cant and progressive CNS involvement. Symptoms 
associated with severe MPS II are usually recognized earlier 
than those the attenuated phenotype. In the earlier reviews, 
Young and Harper reported a mean age of recognition of 
symptoms of approximately 2.47 years, the most common 
presenting feature being developmental delay. The median 
age of recognition of symptoms reported by Schwartz and 
colleagues was only slightly earlier at 2 years (Young et al 
1982; Young and Harper 1983; Schwartz et al 2007). Lifes-
pan in these patients is considerably shortened, commonly 
as a result of pulmonary and/or cardiac disease (Young et al 
1982; Young and Harper 1983). The mean ages of death from 
11.8 to 14.6 years have not changed much in 20 years (Young 
and Harper 1983; Schwartz et al 2007).
Macrocephaly is a common ﬁ  nding, often becoming more 
apparent with age (Young et al 1982). Facial features include 
progressive coarsening, with frontal bossing, prominent 
supraorbital ridge, large nose and ﬂ  at nasal bridge, widely 
spaced teeth, thickened gingival mucosa, and macroglos-
sia, The body habitus is typically broadly built with a short 
neck, broad chest, and protuberant abdomen (Young and 
Harper 1982, 1983; Young et al 1982). The skin is thick and 
hirsutism is common. Individuals may exhibit numerous 
Mongolian spots. Skin-colored papules and nodules (some-
times termed peau d’orange) may be observed, particularly 
on the back, upper arms, shoulders, and thighs, and among 
the MPS disorders, this ﬁ  nding is considered characteristic 
for Hunter syndrome.
Early linear growth is typically normal to advanced, which 
may limit recognition of the disease. The widely recognized 
short stature with contractures develops relatively late when 
compared to features such as hepatosplenomegaly, airway 
disease, and developmental delays. Additionally, patients 
may initially be overweight for age and height (Figure 1).
Corneal clouding, which is observed in other forms 
mucopolysaccharidosis, is characteristically absent in MPS 
II. Refraction errors are frequently identiﬁ  ed on ophthalmo-
logic examination (Schwartz et al 2007). Progressive retinal 
degeneration and optic nerve disease may be observed, 
particularly in severely affected individuals. Papilledema 
may be noted these patients, even in the absence of elevated 
intracranial pressure, possibly a result of glycosaminoglycan 
accumulation within the sclera resulting in compression of 
the optic nerve at the intersceral level (Young and Harper 
1982; Beck and Cole 1984; Neufeld and Muenzer 2001). 
Progressive, mixed conductive and sensorineural hearing 
loss begins in early childhood. The conductive component 
results from eustachian tube dysfunction, thick middle ear 
effusion, and effects of chronic otitis media (Young and 
Harper 1982; Young et al 1982; Young and Harper 1983; 
Neufeld and Muenzer 2001).
Chronic nasal discharge and frequent upper respira-
tory tract infections are common ﬁ  ndings in these patients. 
Progressive deposition of glycosaminoglycans in the larynx 
results in a characteristically hoarse, low pitched voice. Pro-
gressive accumulation of glycosaminoglycans in supraglottic 
tissue, tongue, tonsils, and adenoids, produces mufﬂ  ing of the 
voice, and places individuals at a signiﬁ  cant risk of airway 
obstruction, particularly during sleep and perioperatively. 
Obstructive sleep apnea is a considerable problem for many Biologics: Targets & Therapy 2008:2(2) 313
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individuals, many of whom ultimately require some form 
of therapeutic intervention, including tonsillectomy and/or 
adenoidectomy, positive pressure ventilation, or trache-
ostomy. Lower respiratory illnesses are more common in 
severely affected individuals and become progressively more 
severe and life threatening as the individual’s disease wors-
ens and comorbidities arise. Additionally, rib cage rigidity 
and abdominal distension diminish chest excursion, further 
contributing to pulmonary insufﬁ  ciency (Young and Harper 
1982, 1983; Young et al 1982).
SOURCE: Developed by the National Center for Health Statistics in collaboration with 
                  the National Center for Chronic Disease Prevention and Health Promotion (2000).
                  http://www.cdc.gov/growthcharts
Published May 30, 2000 (modified 11/21/00).
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Figure 1 Growth chart demonstrating the typical growth pattern in patients with Hunter syndrome.Biologics: Targets & Therapy 2008:2(2) 314
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Cardiac disease presents a common source of morbidity 
and mortality in these patients. Accumulation of glycosami-
noglycans within the cardiac valves (speciﬁ  cally mitral and 
aortic valves) results in thickening and abnormal function 
of the valves and impaired cardiac function. Cardiac valve 
replacement has been performed in these patients with suc-
cess (Dangel 1998; Bhattacharya et al 2005). Additionally, 
progressive left ventricular hypertrophy/interventricular 
septal thickening may further lead to impaired cardiac func-
tion (Dangel 1998; Mohan et al 2002).
Hepatosplenomegaly is a consistent feature in MPS II. 
Umbilical and inguinal hernias are frequent, and may recur after 
surgery. Chronic diarrhea is commonly reported in severely 
affected individuals, and may be one of the most distressing 
features of the disease (Young and Harper 1983). Its etiology is 
unclear; however, this symptom may be the result of impaired 
autonomic innervation of the intestines (Elsner 1970).
Skeletal radiographs may demonstrate dysostosis mul-
tiplex, which is characterized by macrocephaly, thickened 
calvarium, and J-shaped sella. The chest demonstrates 
wide, oar shaped ribs, and short, thickened clavicles. The 
spine shows anterior beaking of the lumbar vertebrae. The 
pelvis demonstrates wide, ﬂ  ared ilia, dysplastic acetabulae, 
small, ﬂ  attened femoral heads, and coxa valga. The tubular 
bones exhibit thickened cortices, irregular metaphyses, and 
poorly developed epiphyseal centers. The phalanges are also 
shortened and trapezoidal in shape (Figure 2) (Spranger et al 
2002). Skeletal abnormalities also affect the jaw, leading to 
limited range of motion.
A progressive, destructive arthropathy may affect all the 
joints, particularly the hips, eventually leading to decreased 
range of motion and signiﬁ  cant disability. Physical therapy 
may provide some beneﬁ  t in preserving joint function (Wraith 
et al 2008); however, surgical intervention may eventually 
be required to stabilize and/or repair the damaged joints. 
Progressive joint contractures may be quite debilitating. 
Contractures of the hands, eventually give rise to a claw-like 
hand deformity. Carpal tunnel syndrome is a common, albeit 
frequently overlooked manifestation that may become quite 
severe, ultimately requiring surgical intervention (Haddad 
et al 1997). Progressive motor impairment into early adult-
hood has been documented using Functional Independence 
Measures (Kato et al 2007).
Progressive neurologic deterioration characterizes the 
severe phenotypes of MPS II with slow global acquisition 
of developmental milestones during the preschool years. 
Behavior problems, particularly aggressiveness and hyper-
activity, may be signiﬁ  cant and quite taxing on care givers 
(Young and Harper 1981). A plateau occurs around age 6, 
followed by progressive neurological deterioration. In the 
late stages of the disease, individuals are severely impaired 
and dependent upon caregivers for all their needs (Young and 
Harper 1983). Pyramidal tract disease, ie increased muscle 
tone, exaggerated deep tendon reﬂ  exes, and ankle clonus has 
been observed (Young and Harper, 1982, 1983; Young et al 
1982). Seizure activity, reported in 18% of individuals in the 
Hunter Outcome Survey (HOS) registry (Wraith et al 2007) 
appears in the ﬁ  rst decade of life, and is usually amenable 
to antiepileptic therapy. Communicating hydrocephalus 
may develop during the end of ﬁ  rst decade of life, further 
contributing to the neurologic deterioration (Neufeld and 
Muenzer 2001).
In individuals with attenuated disease, cognitive dete-
rioration does not occur and the prevalence of neurologic 
manifestations is decreased compared to severely affected 
individuals. Nonetheless, abnormal MRI ﬁ  ndings, including 
volume loss and white matter lesions, are seen in individuals 
with the attenuated form (Parsons et al 1996). Individuals are 
expected to have normal intelligence to mild delays. How-
ever, certain medical comorbities, ie, deafness and decreased 
joint mobility, may contribute to problems in school. The 
behavioral problems observed in severely affected individu-
als do not occur; however, these individuals may have psy-
chological problems related to their medical comorbidities 
and adjustment to their disease (Young and Harper 1981).
Figure 2 X-ray of the hand demonstrating the typical radiographic ﬁ  ndings in patients 
with Hunter syndrome. The small density over the proximal hypothenar eminence in 
this image represents a foreign body.Biologics: Targets & Therapy 2008:2(2) 315
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Spinal cord compression is one of the most serious 
complications of MPS II, and can lead to permanent neuro-
logic damage or death, if not detected and treated early. This 
may result from foramen magnum and vertebral canal ste-
nosis, meningeal thickening from glycosaminoglycan accu-
mulation, and less commonly from atlanto-axial subluxation 
(Parsons et al 1996; O’Brien et al 1997).
The work of Young and Harper (Young and Harper 1981, 
1982, 1983; Young et al 1982) and others has contributed 
signiﬁ  cantly to our understanding of the clinical features of 
MPS II. However, these studies were conducted prior to the 
availability of modern supportive and deﬁ  nitive medical care. 
Comprehensive studies addressing the effectiveness of newer 
medical techniques in treating patients with MPS II are only 
beginning to appear in the literature. It is anticipated that 
rare disease registries such as the Hunter Outcome Survey, 
sponsored by Shire HGT Pharmaceuticals, will provide an 
opportunity to assess both the natural history and effect of 
interventions on patients currently cared for in participating 
centers. Preliminary ﬁ  ndings from the HOS as well as a 
similar review of the clinical manifestations and treatment 
of MPS II were recently reported by Wraith and colleagues 
(Wraith et al 2008).
Molecular
Iduronate-2-sulfatase, a member of the sulfatase family, 
catalyzes the removal of the sulfate group from the 
2- position of L-iduronic acid in dermatan sulfate and 
heparan sulfate in lysosomes (Neufeld and Muenzer 2001). 
IDS, which is located at Xq28, spans approximately 24 kb, 
consists of 9 exons and 8 introns, and has a coding sequence 
of 2.3 kb. A pseudogene, IDS2, located approximately 
20 kb distal to the gene, contains sequences homologous to 
exon II, exon III, intron 2, and a chimeric intron3-intron7 
(Froissart et al 2002). Its exact function is unclear; how-
ever, pathogenic structural rearrangements between IDS2 
and IDS have been identiﬁ  ed in individuals with MPS 
II. Sequence analysis of human IDS cDNA predicts the 
translation of a 550 amino acid precursor peptide, includ-
ing a 25 amino acid amino-terminal signal sequence and 
eight additional amino acids that are removed from the 
proprotein (Wilson et al 1990).
IDS has a strong sequence homology to other human 
sulfatases, including arylsulfatases A, B, and C, and 
glucosamine-6-sulfatase (Wilson et al 1990). All members 
of the sulfatase family undergo post-translational modiﬁ  ca-
tion in the endoplasmic reticulum during which a conserved 
cysteine residue located within the active site is converted 
into Cα-formylglycine by formylglycine-generating enzyme 
(FGE). Cα-formylglycine is essential for catalytic activity 
of the sulfatases. Mutations in SUMF1, which codes for 
FGE, results in severely reduced activity of the sulfatases, 
leading to multiple sulfatase deﬁ  ciency, an autosomal reces-
sive disorder, the phenotype of which combines features of 
disorders resulting from individual sulfatase deﬁ  ciencies 
(Dierks et al 2003).
The Human Gene Mutation Database (HGMD) pres-
ently documents 345 disease causing mutations in IDS 
(Krawczak and Cooper 1997; Stenson et al 2003), many of 
which are private. They include missense, nonsense, splice 
site mutations, small insertions and deletions, partial and 
whole gene deletions, and large rearrangements (Stenson 
et al 2003). Approximately 12% of cases arise de novo 
from maternal meiosis (Rathmann et al 1996; Vaﬁ  adaki 
et al 1998). Approximately 80% of all cases of MPS II result 
from small deletions, insertions, or single base substitutions, 
while the remaining 20% of cases result from large scale 
deletions in IDS or structural rearrangements (Hopwood 
et al 1993; Froissart et al 2007). Point mutations account for 
approximately 50% of all mutations, and tend occur more 
frequently in exons III, VIII, and IX, particularly at CpG 
sites (Rathmann et al 1996).
The identiﬁ  cation of genotype-phenotype correlations in 
MPS II has been challenging for several reasons. Measured 
IDS activity in plasma or circulating cells does not differ-
entiate between severe or attenuated forms, suggesting that 
the differences in disease threshold fall below the range of 
measurable enzyme activity. There is currently no standard-
ized severity scoring system, although these tools are being 
developed as therapeutic options are brought into clinical 
application. There is broad degree of genotypic heterogene-
ity, and a signiﬁ  cant number of private mutations exist in this 
disease (Froissart et al 2002, 2007). Despite these limitations, 
certain genotype/phenotype correlations have been described. 
Large gene alterations (deletions and rearrangements) are 
typically associated with severe disease phenotypes because 
of a complete absence of functional enzyme. Other genes, 
including FMR-1 may also be deleted, further contributing 
to the severe phenotypes, particularly development of mental 
retardation (Froissart et al 2007).
Splice site mutations affecting consensus sequences, 
small deletions or insertions causing frameshifts, and non-
sense mutations are generally associated with intermediate 
and severe phenotypes (Hopwood et al 1993; Froissart 
et al 1998, 2002; Vaﬁ  adaki et al 1998). However, there are 
exceptions: The nonsense mutation Q513X is associated Biologics: Targets & Therapy 2008:2(2) 316
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with an attenuated phenotype because the encoded amino 
acid product lacks 19 C-terminal amino acids normally 
removed during protein maturation (Froissart et al 2002). 
The effects of splice site mutations are variable, depending 
on the location and nature of the mutation and presence of 
normal transcripts. Affected individuals may produce the 
normal gene transcript in sufﬁ  cient, albeit low, levels to 
avoid developing a severe phenotype.
The effects of missense mutations and small in-frame 
deletions and insertions are often difﬁ  cult to predict, and 
expression studies are sometimes needed to differentiate a 
polymorphism from a disease-causing mutation (Froissart 
et al 2002). Missense mutations that do not signiﬁ  cantly 
impact protein folding and/or enzyme activity are predicted 
to result in attenuated phenotypes. Conversely, missense 
mutations affecting sequences highly conserved among the 
sulfatases generally result in a severe disease phenotype 
(Froissart et al 1998).
Animal studies
A knockout mouse model of MPS II (ids y/-) has been devel-
oped by replacing exon 4 and a portion of exon 5 of IDS with 
the neomycin resistance gene (Muenzer et al 2002; Garcia 
et al 2007b). Affected mice exhibit many of the features 
observed in humans, including elevated urine glycosami-
noglycan excretion, accumulation of glycosaminoglycans 
in tissues and organs, and deﬁ  cient iduronate-2-sulfatase 
enzyme activity. Clinical features include hepatospleno-
megaly, progressive skeletal abnormalities, and premature 
death (Garcia et al 2007b).
Garcia and colleagues studied the effects of idursulfase 
on the IdS-KO (ids y/-) mouse model (Garcia et al 2007a). 
Idursulfase infused at various doses (0.1, 0.25, 0.5, and 
1.0 mg/kg) and dosing frequencies (once, weekly, every 
other week, and monthly), resulted in a reduction in urine 
and tissue glycosaminoglycan levels. Additionally, liver 
weight was signiﬁ  cantly reduced after 24 weeks of therapy 
in mice treated with 1 mg idursulfase weekly and every other 
week. This study provided further proof of the principle that 
some histological and biochemical features of MPS II can be 
effectively reversed with enzyme replacement therapy.
A gene therapy technique using the AAV2/8 vector 
to selectively deliver human IDS cDNA to the liver in 
the ids y/- mouse model resulted in a restoration of plasma and 
tissue IDS activity in the treated mice (Cardone et al 2006). 
Consequently, normalization of urine glycosaminoglycan 
levels and clearance of glycosaminoglycan accumulation 
within the visceral tissues was observed. Corrections of the 
skeletal and locomotor defects were also observed in treated 
mice. Interestingly, partial clearance of glycosaminoglycans 
and improved IDS activity in the CNS were also reported, 
including uptake of human IDS into the lysosomes of the 
cortex and cerebellum. These results suggest that signiﬁ  -
cant overexpression of IDS in peripheral (liver) tissue may 
allow penetration of IDS at low levels past the blood brain 
barrier.
Friso and colleagues (Friso et al 2005) evaluated an 
alternate delivery system by intraperitoneally implanting 
alginate microcapsules containing C2C12 murine myoblasts 
overexpressing IDS into ids y/- mice. Detectable levels of 
IDS in plasma and tissues of implanted ids y/- mice were 
found at 3 days and 2 weeks, respectively and persisting at 
8 weeks of therapy. Urine glycosaminoglycan excretion was 
signiﬁ  cantly decreased in implanted knockout mice between 
weeks 4 and 6 of therapy. Additionally, a signiﬁ  cant decrease 
in tissue glycosaminoglycan accumulation was noted bio-
chemically in the kidney and spleen after 8 weeks of therapy. 
Decreased tissue glycosaminoglycan accumulation was also 
apparent histologically in the liver, spleen, and kidney after 
8 weeks of therapy.
Therapy
The management of MPS II requires lifelong attention to the 
multisystemic involvement by a team of specialists experi-
enced in the management of this disease since none of the 
therapeutic options currently available result in complete 
resolution of morbidity.
HSCT has been successful in improving certain disease 
manifestations in patients with mucopolysaccharidosis type I 
(MPS I, Hurler syndrome), including visceral manifestations 
and attenuation of neurologic disease progression when per-
formed early (ie, less than 2 years of age), and is considered 
a mainstay in the treatment of severe MPS I. HSCT has been 
performed in numerous individuals with MPS II. In some 
cases, individuals demonstrate improvement of the visceral 
and skeletal manifestations of the disease, ie, decreased 
urine glycosaminoglycan excretion, decreased liver and 
spleen volumes, diminished facial coarsening, improved 
respiratory function, and increased joint mobility (Coppa 
et al 1995; McKinnis et al 1996; Mullen et al 2000; Froissart 
et al 2002). However, HSCT does not appear to mitigate the 
progressive neurodegenerative disease often present in MPS 
II (Coppa et al 1995; Shapiro et al 1995; McKinnis et al 1996; 
Vellodi et al 1999). Additionally, this technique is associated 
with a signiﬁ  cant risk of morbidity and mortality. For these 
reasons, and with the advent of enzyme replacement therapy Biologics: Targets & Therapy 2008:2(2) 317
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(discussed below), HSCT has limited, if any, utility in the 
treatment of MPS II.
Elaprase® (idursulfase; Shire HGT Pharmaceuticals, 
Cambridge, MA) was approved in the US in July, 2006 and 
Europe in January, 2007 for the treatment of individuals 
with MPS II at a recommended dose of 0.5 mg/kg admin-
istered once weekly as an intravenous infusion. Idursulfase 
is a puriﬁ  ed form of iduronate-2-sulfatase produced in a 
human cell line via recombinant DNA technology. The 525 
amino acid glycoprotein contains 8 N-linked glycosylation 
sites that are occupied by 2 bis mannose-6-phosphate 
containing oligosaccharide chains (Muenzer et al 2006). 
These mannose-6-phosphate (M6P) chains bind to M6P 
receptors on the cell surface, allowing for subsequent 
internalization and trafﬁ  cking to the lysosomes, where 
the enzyme is catalytically active. The enzyme activity 
of idursulfase is dependent upon the post-translational 
modiﬁ  cation of cysteine to Cα-formylglycine within the 
enzyme’s active site. This modiﬁ  cation was demonstrated 
in 50% of the molecules of idursulfase (Muenzer et al 
2006). Idursulfase also contains complex, highly sialylated 
glycans that prolong the circulating half-life of the drug 
(Muenzer et al 2006).
The safety and efﬁ  cacy of idursulfase was evaluated in 
a randomized, double-blinded, placebo controlled phase I/II 
clinical trial (Muenzer et al 2007). In this study, 12 partici-
pants, between the ages of 6 and 20, who met clinical and 
biochemical criteria for MPS II and were able to cooperate 
with all study procedures (which excluded severely affected 
MPS II patients), received idursulfase at doses of 0.15, 0.5, 
or 1.5 mg/kg or placebo infused once per week over a period 
of 24 weeks, followed by a 6-month open-label extension 
study in which all participants received idursulfase. Clinical 
endpoints were evaluated after 48 weeks of therapy with 
active agent and compared with the three patients observed 
over 24 weeks of placebo infusions.
Urine glycosaminoglycan excretion was reduced within 
2 weeks of initiating idursulfase, and continued to be sig-
niﬁ  cantly reduced after 48 weeks of therapy (p   0.0001). A 
majority of patients experienced reductions of urine GAGs 
to near normal levels, while two individuals achieved urine 
GAGs within the normal range after 6 months. Liver and 
spleen volumes were signiﬁ  cantly decreased in the pooled 
study population after 24 and 48 weeks of therapy (p   0.01 
and p   0.001, respectively). Sixty-six percent of individuals 
with baseline hepatomegaly and all individuals with baseline 
splenomegaly experienced a normalization of organ volumes. 
Finally, after 48 weeks of therapy, average walking distance 
of the combined groups increased by an average of 48 m 
(p = 0.013).
In a follow-up phase II/III clinical study, the safety and 
efﬁ  cacy of idursulfase was evaluated in 96 patients, ages 
5–31, with MPS II (Muenzer et al 2006). In this study design, 
patients were randomized to receive placebo or idursulfase 
0.5 mg/kg weekly or every other week, for 53 weeks, fol-
lowed by an open-label extension. Participants met clinical 
and biochemical criteria for MPS II, were able to cooperate 
with all study procedures (excluding severely affected MPS 
II patients), and had a baseline forced vital capacity (FVC) 
less than 80% of predicted. The primary endpoint of the 
study was a 2-component composite score of %FVC and 
the 6-minute walk test.
After 53 weeks of therapy, patients in the weekly and 
every other week idursulfase groups exhibited signiﬁ  cant 
improvement in the 2-component composite endpoint com-
pared to placebo (p = 0.0049 and p = 0.0416, respectively). 
However, there was no difference between the two idursul-
fase treatment groups. The weekly idursulfase treatment 
group experienced a 37 m increase in distance walked in 
the 6-minute walk test (P = 0.013) compared to placebo. 
Additionally, the weekly idursulfase treatment group expe-
rienced a 2.7% increase in predicted %FVC (p = 0.065) and 
a 160 mL increase in absolute FVC (p = 0.001) compared 
to placebo at 53 weeks.
After 53 weeks of therapy, urine glycosaminoglycan lev-
els were signiﬁ  cantly decreased in both idursulfase treatment 
groups compared to placebo (p   0.0001). After 53 weeks of 
therapy, 40.6% of individuals in both idursulfase treatment 
groups experienced normalization of urine GAG levels, while 
urine GAG levels approached the upper end of normal in a 
majority of the remaining patients treated with idursulfase. 
Liver and spleen volumes diminished signiﬁ  cantly from 
baseline in both idursulfase treatment groups, compared with 
placebo (p   0.0001). Approximately 80% of individuals 
with baseline hepatomegaly who received treatment with 
idursulfase (weekly and every other week) had normal liver 
volumes after 18 and 53 weeks of therapy.
Idursulfase was generally well tolerated in the phase 
I/II and phase II/III clinical trials. The most frequently 
reported adverse events included fever, headache, cough, 
pharyngitis, upper respiratory tract infection, nasal conges-
tion, nausea, vomiting, abdominal pain, and diarrhea. Of the 
adverse events considered possibly related to idursulfase 
therapy, infusion-related events were the most common. The 
incidence of infusion-related events was greatest between 
weeks 4 and 12 and decreased subsequently. These events Biologics: Targets & Therapy 2008:2(2) 318
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were generally managed by stopping the initial infusion and 
premedicating with antihistamines and/or corticosteroids 
prior to subsequent infusions. If a reaction occurred during 
subsequent infusions, the infusion was stopped and restarted 
after the reaction resolved. Two deaths occurred during the 
phase II/III study, neither of which was considered to be 
related to idursulfase therapy.
IgG antibodies to idursulfase were detected in approxi-
mately 50% of patients, the highest prevalence of which 
occurred after 27 weeks of therapy (44.4% of patients). 
However, only 31.7% of patients in the idursulfase treatment 
groups remained antibody positive after 53 weeks of therapy. 
Although the presence of IgG anti-idursulfase antibodies 
was associated with an approximately two thirds reduction 
in urine glycosaminoglycan excretion in the phase II/III 
clinical trial, there was reportedly no association between 
the presence of antibodies and adverse events or clinical 
assessments. IgE antibodies to idursulfase were not detected 
in either study.
Patients receiving ERT should be monitored carefully 
during the infusion and for a period afterwards for an infu-
sion related reaction to idursulfase. Additionally, easy access 
to emergency equipment/medications by skilled providers 
should be available. Initial infusion-related reactions are 
usually managed by discontinuing the infusion and pro-
viding antihistamines and/or corticosteroids. Subsequent 
infusions may be managed by slowing the infusion rate and 
pre-treating with antihistamines and/or corticosteroids. If a 
subsequent reaction occurs, the infusion should be stopped 
and appropriate treatment provided. Depending upon the 
severity of the reaction, the infusion may be restarted upon 
resolution of the reaction.
Patients with compromised respiratory function or acute 
respiratory disease may be at an increased risk of experienc-
ing a severe infusion-related reaction. Recently, two patients 
experienced late-emergent anaphylactoid reactions approxi-
mately 24 hours after having experienced initial anaphylactic 
reactions during enzyme infusions. Thus, prolonged obser-
vation times are indicated in certain populations (Elaprase® 
package insert).
Idursulfase has been studied only in patients with attenu-
ated disease. Consequently, the effects of idursulfase on 
CNS disease have not been formally evaluated. However, 
idursulfase does not cross the blood–brain barrier; thus it is 
not expected to have a signiﬁ  cant effect on the neurological 
features of MPS II. Whether ERT should be offered to indi-
viduals with CNS manifestations is unclear. Wraith and col-
leagues suggest that patients with severe CNS manifestations 
be offered ERT for a trial period of 12–18 months, after 
which time a decision is made whether to continue with the 
therapy (Wraith et al 2008).
Idursulfase has not been studied in patients younger than 
5 years of age. Many patients under 5 years are currently 
being treated and there is no reason to think that ERT would 
be less effective for the visceral manifestations in these young 
patients. Evaluation of the long term efﬁ  cacy and safety of 
idursulfase in these populations are needed.
While ERT is expected to provide a beneﬁ  t to patients 
receiving the therapy, it is not without a signiﬁ  cant ﬁ  nancial 
and emotional burden. ERT using idursulfase is expensive, 
with an estimated average annual cost of US$491,999.04 in 
a 30 kg child, based upon the US average wholesale price 
obtained from the Red Book Database (http://micromedex.
com/products/redbook/database/). However, the actual 
cost of ERT will vary depending upon the individual’s 
weight, and amount of drug prescribed. Additionally, other 
fees, including a markup on the drug from the hospital, 
private ofﬁ  ce and infusion center, and for supplies may be 
incurred. Insurance coverage may present a signiﬁ  cant issue 
for patients. For example, premiums may become unaf-
fordable for individuals with private insurance coverage. 
Additionally, the lifetime maximums in many policies will 
be exceeded in several years given the expense of the drug 
and other costs. Shire HGT Pharmaceuticals has developed a 
Patient Assistance Program that offers assistance to qualiﬁ  ed 
patients on a case by case basis, primarily based on ﬁ  nancial 
need. Private organizations, eg, the National Organization 
for Rare Disorders, also have programs to assist families 
with ﬁ  nancial costs related to ERT and healthcare coverage 
(Burrow et al 2007).
ERT infusions in a hospital/infusion center environment 
frequently require patients and their families to take time off 
of work/school to receive treatments, further contributing 
to their emotional/ﬁ  nancial burden. In patients who have 
previously tolerated infusions without reactions, or mild 
reactions easily treated with antipyretics/antihistamines and/
or slowed infusion rates, transferring patients to receiving 
infusions in the home setting is a plausible option (Wraith 
et al 2008). However, this transition should be performed 
with consideration given these patients’ complex medical 
histories, the “black box warning” on the label, and recent 
reports of late-emergent anaphylactoid reactions in patients 
treated with idursulfase. In patients who are transitioned to 
home infusions, a skilled home care nurse should be present 
and easy access to emergency equipment/medications in case 
of reactions should be available.Biologics: Targets & Therapy 2008:2(2) 319
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Alternative methods aimed at directly targeting enzyme 
to the CNS, ie, intrathecally, have been previously evalu-
ated in MPS I animal models (Dickson et al 2007). A study 
evaluating the safety and efﬁ  cacy of intrathecal ERT in the 
treatment of certain spinal cord manifestations of MPS I is 
currently recruiting participants. Intrathecal trials of ERT 
for MPS II are planned. However, the differences between 
the cognitive and behavioral manifestations in MPS I and II, 
and the difference in response to HSCT are reminders that a 
therapy with efﬁ  cacy in one of the MPS disorders may have 
different outcomes in another.
Newer treatment modalities, ie, pharmacological chaperone 
and substrate reduction therapy, are being developed for patients 
with other lysosomal storage diseases, including Gaucher 
disease (Cox et al 2000; Elstein et al 2004; Yu et al 2007a, b). 
Pharmacological chaperone therapy is a therapeutic approach 
in which small molecules selectively bind to and stabilize the 
structure of target proteins in cells, allowing for improved 
folding and trafﬁ  cking to the lysosomes and increased protein 
activity. Substrate reduction therapy is a therapeutic approach 
in which in which a pharmacologic agent decreases the produc-
tion of the molecule that typically accumulates within the cells 
in individuals with a lysosomal storage disease so that the 
patient’s residual enzyme may catabolize the accumulated 
material. There are no current clinical trials examining these 
therapies in MPS II, and the prospects for chaperone therapy 
are low if there is no residual enzyme to protect.
Gene therapy offers signiﬁ  cant potential for the treat-
ment/cure of genetic diseases such as MPS II and several 
attempts to express iduronate sulfatase through gene therapy 
approaches have been investigated (Stroncek et al 1999; Hong 
et al 2003). Although gene therapy remains a viable potential 
option, safety issues and problems with robust expression in 
vivo remain barriers to its clinical application.
Conclusions
MPS II is a heterogeneous, progressive X-linked lysosomal 
storage disease, the management of which requires lifelong 
attention to the multisystem involvement, Recent clinical 
trials have demonstrated that enzyme replacement therapy 
with intravenous idursulfase is a safe and effective treatment 
modality for the somatic, but likely not the CNS manifesta-
tions of MPS II. As with other lysosomal storage disorders, 
enzyme replacement therapy represents a treatment rather 
than a cure for this disease; long term studies evaluating the 
efﬁ  cacy of this therapy are indicated.
Approaches which are likely to ameliorate the progres-
sive CNS manifestations in children with severe MPS II are 
still in preclinical stages, and will be a needed addition to the 
therapeutic armamentarium for this condition.
It is anticipated that rare disease registries such as the 
HOS will provide a mechanism through which experience 
beyond clinical trials can be documented and made available 
to centers which care for these patients.
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